New drug 'Mylotarg' for AML makes another attempt at reimb
By Eo, Yun-Ho | translator Kang, Shin-Kook
24.06.27 05:16:04
가나다라
0
Pfizer Korea has submitted an application for insurance listing
Mylotarg improved survival in CD33-positive adult patients

▲Pfizer Korea’s Mylotarg (gemtuzumab ozogamicin), a treatment for acute myeloid leukemia (AML).
A new drug 'Mylotarg' for the treatment of acute myeloid leukemia (AML) is making another attempt to obtain insurance reimbursement listing.
According to industry sources, Pfizer Korea has recently reapplied for reimbursement review for Mylotarg (gemtuzumab ozogamicin), a treatment for acute myeloid leukemia (AML).
In May 2022, Mylotarg was considered for review by the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HIRA). However, it received a decision of unestablished reimbursement criteria. It passed the Cancer Disease Review Committee review in October last year, but the subsequent decision was canceled.
It is to be watched whet
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)